Abstract
NY-ESO-1 is frequently expressed in epithelial ovarian cancer (EOC) and elicits spontaneous humoral and cellular immune responses in a proportion of EOC patients. The identification of NY-ESO-1 peptide epitopes with dual HLA-class I and class II specificities might be useful in vaccination strategies for generating cognate CD4+ T cell help to augment CD8+ T cell responses. Here, we describe two novel NY-ESO-1-derived MHC class I epitopes from EOC patients with spontaneous humoral immune response to NY-ESO-1. CD8 + T cells derived from NY-ESO-1 seropositive EOC patients were presensitized with a recombinant adenovirus encoding NY-ESO-1or pooled overlapping peptides. These epitopes, ESO127-136 presented by HLA-A68 molecule, and ESO127-135 restricted by HLA-Cw15 allele, are located within ESO119-143, a promiscuous HLA-class II region containing epitopes that bind to multiple HLA-DR alleles. The novel epitopes were naturally processed by APC or naturally presented by tumor cell lines. In addition, these epitopes induced NY-ESO-1-specific CTL in NY-ESO-1 seropositive EOC patients. Together, the results indicate that ESO119-143 epitope has dual HLA classes I and II specificities, and represents a potential vaccine candidate in a large number of cancer patients.
Original language | English (US) |
---|---|
Pages (from-to) | 1185-1195 |
Number of pages | 11 |
Journal | Cancer Immunology, Immunotherapy |
Volume | 57 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2008 |
Keywords
- CD8
- Epithelial ovarian cancer
- Epitope
- MHC class I
- NY-ESO-1
- Tumor immunity
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
- Cancer Research